HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Analysis of the duration of migraine prophylaxis.

Abstract
To determine the minimum duration of migraine prophylaxis, after patients become pain-free. Migraine patients diagnosed according to criteria of International Classification of Headache Disorders-2 were treated prophylactically. After becoming pain-free, they were divided into two equal groups: in group 1, prophylaxis was maintained for another 12 months and in group 2, for 24 months. Each group was followed for more three years after prophylaxis period. Of the 50 patients, 39 (78%) were female and 11 (22%) were male. The age ranged from 18 to 50 years. Before treatment, the attack frequency for groups 1 and 2 was, respectively, 16.3 ± 12.8 and 16.4 ± 11.8 days per month (p = 0.769). Patients in groups 1 and 2 have become pain-free, respectively, with 21.4 ± 11.2 and 16.8 ± 9.9 months (p = 0.161). During three years without treatment, groups 1 and 2 maintained an annual frequency of respectively 3.2 and 0.5 headache days. Of the patients in group 2, 76.0% (19/25) remained pain-free during follow-up, versus 44.0% (11/25) of group 1, with a significant difference (p=0.001). The best results were obtained when migraine prophylaxis was maintained for 24 months after patients became pain-free.
AuthorsRaimundo Pereira Silva-Néto, Kelson James Almeida, Silvya Neri Bernardino
JournalJournal of the neurological sciences (J Neurol Sci) Vol. 337 Issue 1-2 Pg. 38-41 (Feb 15 2014) ISSN: 1878-5883 [Electronic] Netherlands
PMID24308946 (Publication Type: Journal Article, Randomized Controlled Trial)
CopyrightCopyright © 2013 Elsevier B.V. All rights reserved.
Chemical References
  • Vasodilator Agents
  • Atenolol
  • Nortriptyline
  • Flunarizine
Topics
  • Adolescent
  • Adult
  • Atenolol (therapeutic use)
  • Dose-Response Relationship, Drug
  • Female
  • Flunarizine (therapeutic use)
  • Humans
  • International Classification of Diseases
  • Male
  • Middle Aged
  • Migraine Disorders (diagnosis, drug therapy, prevention & control)
  • Nortriptyline (therapeutic use)
  • Prospective Studies
  • Time Factors
  • Treatment Outcome
  • Vasodilator Agents (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: